DIFFUSE BIO
DEAD

Serial Number

98042423

Owner

Diffuse Bio, Inc.

Attorney

RAJESH FOTEDAR

Filing Date

Jun 14, 2023

Add to watchlist:

No watchlists yet
View on USPTO

DIFFUSE BIO Trademark

Serial Number: 98042423

DIFFUSE BIO is a trademark filed by Diffuse Bio, Inc. on June 14, 2023. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Diffuse Bio, Inc.

733 Industrial Road,
San Carlos, CA 94070

Entity Type: 03

Trademark Details

Filing Date

June 14, 2023

Registration Date

Not Registered

Published for Opposition

October 15, 2024

Goods & Services

Downloadable computer software using artificial intelligence for pharmaceutical drug design and development; Downloadable computer software using artificial intelligence for pharmaceutical drug design and development for treating target disease identified by a customer; Downloadable computer software using artificial intelligence for pharmaceutical drug design and development for treating target disease identified by a customer, namely, a pharmaceutical company; Downloadable computer software for pharmaceutical drug design and development according to artificial intelligence substituted for physical experimentation

Providing temporary use of on-line non-downloadable computer software using artificial intelligence for pharmaceutical drug design and development; Providing temporary use of online non-downloadable computer software using artificial intelligence for pharmaceutical drug design and development for treating target disease identified by a customer; Providing temporary use of on-line non-downloadable computer software using artificial intelligence for pharmaceutical drug design and development for treating target disease identified by a customer, namely, a pharmaceutical company; Providing temporary use of on-line non-downloadable computer software for pharmaceutical drug design and development according to artificial intelligence substituted for physical experimentation; Software as a Service (SaaS) services featuring artificial intelligence software for pharmaceutical drug design and development; SaaS services featuring artificial intelligence software for pharmaceutical drug design and development for treating target disease identified by a customer; SaaS services featuring artificial intelligence software for pharmaceutical drug design and development for treating target disease identified by a customer, namely, a pharmaceutical company; SaaS services featuring software for pharmaceutical drug design and development according to artificial intelligence substituted for physical experimentation; Pharmaceutical research services for the discovery of authentic clinical drug candidates, namely, design, analysis, testing, optimization, and profiling of druglike compounds

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 29, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 29, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 15, 2025 EXRA
SOU EXTENSION 1 GRANTED
May 28, 2025 EX1G
SOU EXTENSION 1 FILED
May 27, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
May 27, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 26, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 15, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 15, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 25, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 10, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 6, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 6, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 6, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
May 30, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
May 30, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 8, 2024 GNRN
NON-FINAL ACTION E-MAILED
Mar 8, 2024 GNRT
NON-FINAL ACTION WRITTEN
Mar 8, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 4, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 21, 2023 NWOS
NEW APPLICATION ENTERED
Jun 17, 2023 NWAP